TimeTeller launches saliva test to align cancer therapy with patients’ circadian clocks

TimeTeller, a Berlin-originated health-tech company, unveiled its at-home saliva test for circadian rhythm profiling at TechCrunch Disrupt in San Francisco. The startup has already secured a reimbursement agreement with Techniker Krankenkasse, one of Germany’s largest insurers, and plans to extend the offering to the insurer’s 12 million members. The move positions the company at the intersection of personalized medicine and everyday health monitoring.

The company is led by CEO Angela Relógio, a physicist-engineer and molecular biologist who spent years researching oncology, circadian biology, and systems medicine in German academic labs. Relógio left academia after observing that many cancer patients altered or halted treatment because of side effects, and she hypothesized that the timing of drug administration could be a missing factor. She personally funded the first patent on the circadian assay and later spun the venture out of Berlin’s Charité university hospital before relocating to the Medical School Hamburg, which provided patient access, research funding, and a safety-net employment arrangement for the ten-person team.

TimeTeller’s core product is a saliva-based kit that determines an individual’s internal clock. While the test can inform lifestyle recommendations, such as sleep schedules, nutrition, light exposure, and exercise, it does not, on its own, prescribe optimal dosing times for specific medicines. Relógio emphasizes that translating a circadian profile into a treatment schedule requires clinical study data for each drug. “We calculate the optimal timing within the context of clinical trials,” she said at the event.

The company’s initial market traction came from longevity clinics that focus on healthy aging and see value in circadian data for personalized advice. Beyond cancer, Relógio sees potential applications in metabolic disorders like diabetes, neurodegenerative conditions such as Alzheimer’s disease, performance optimization, and women’s health. Nevertheless, the startup’s primary mission remains oncology, where aligning chemotherapy or immunotherapy with a patient’s biological rhythm could reduce toxicity and improve efficacy.

Co-founder Benjamin Dose, a biochemist with market-access expertise, helped negotiate the partnership with Techniker Krankenkasse. The insurer began by reimbursing the test for a limited cohort of cancer patients, and both parties are now preparing to roll the benefit out to a broader population. The collaboration gives TimeTeller a direct pathway to thousands of insured individuals while providing the insurer with a data-driven tool to potentially lower treatment costs associated with adverse events.

Looking ahead, Relógio envisions a healthcare landscape where the question “when” is as central as “what” in prescribing medication. She argues that virtually every physiological process follows a daily rhythm, and that integrating timing into precision medicine could reshape therapeutic standards. As the company scales its consumer kit and deepens clinical collaborations, the key challenge will be generating robust evidence that circadian-guided dosing translates into measurable patient outcomes. Success on that front could make TimeTeller’s modest saliva test a cornerstone of future treatment protocols.